Trial Profile
Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Obefazimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Abivax
- 01 Mar 2021 Results assessing and efficacy and safety from TRACK study at 8 weeks and from long-term extension study at months 12 and 24 published in the Gastroenterology
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism